The United States Food and Drug Administration (US FDA) has approved the cholesterol-lowering drug bempedoic acid, the use of which reduces the risk of cardiac adverse events.
Statin therapy – the gold standard in treating excessive ‘bad’ cholesterol levels, may impose severe side effects in a few. A new study presented at the annual meeting of the American College of Cardiology unraveled the benefits of bempedoic acid in patients who cannot tolerate statins.
The lead author, Dr. Steven E. Nissen, stated that 7-29% of patients experience adverse effects after statin therapy; the majority report muscular pain. Bempedoic acid use is not associated with muscular side effects and is activated only when it enters the biliary system.
Although this drug reduces the risk of heart attacks (by 23%) and chances of undergoing major cardiovascular procedures like cardiac revascularization (by 19%), there is a mild increased risk of gout and gallbladder stones with its use. Bempedoic acid can also be used as an adjunct to statin therapy.
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
Please login to comment on this article